.Attributes Medication, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medication conjugate (ADC) tisotumab vedotin resulted in enhanced progression-free and overall survival, leading to FDA commendation and also a new procedure option for people.